

Please amend Claim 14 as follows:

*132* 14. (Amended) The method of Claim 1, wherein the bombesin receptor antagonist is administered in combination with alprostadil or phentolamine.

Please cancel Claim 15.

Please amend Claim 16 as follows:

*133* 16. (Amended) The method of Claim 1, wherein the bombesin receptor antagonist is administered in combination with a compound that promotes production of NO.

Please amend Claim 21 as follows:

*134* 21. (Amended) The method of Claim 1, wherein the bombesin receptor antagonist and a vasodilator are simultaneously administered to the subject in the form of a composition containing a unit dose of the bombesin receptor antagonist, a unit dose of the vasodilator and pharmaceutically acceptable carrier or diluent.

Please add the following new Claims 24 - 46:

*135* -- 24. (New) The method of claim 5, wherein the sexual dysfunction is hypoactive sexual desire disorder.

25. (New) The method of claim 5, wherein the sexual dysfunction is a sexual arousal disorder.

26. (New) The method of claim 5, wherein the sexual dysfunction is an orgasmic disorder or anorgasmia.

27. (New) The method of claim 5, wherein the sexual dysfunction is sexual pain disorder.

28. (New) The method of claim 5, wherein the subject is receiving an antidepressant or antihypertensive.
29. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a vasodilator which acts on local blood flow at the clitoris or vagina or on lubricant secretion.
- cont*  
*35*
30. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a PDE5 inhibitor.
31. (New) The method of claim 30, wherein the PDE5 inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.
32. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a VIP enhancer.
33. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor.?
34. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an oestrogen.
35. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with an androgen.
36. (New) The method of claim 5, wherein the bombesin receptor antagonist is administered to the subject in combination with a neurotransmitter modulator.
37. (New) The method of claim 6, wherein the sexual dysfunction is erectile dysfunction.
38. (New) The method of claim 6, wherein the sexual dysfunction is psychogenic.

39. (New) The method of claim 6, wherein the sexual dysfunction is drug-induced.

40. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a vasodilator which acts on local blood flow at the penis.

*cont*  
**B5**

41. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a PDE5 inhibitor.

42. (New) The method of claim 6, wherein the PDE5 inhibitor is sildenafil or a pharmaceutically acceptable salt thereof.

43. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a VIP enhancer.

44. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with an angiotensin-2 receptor.

45. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with an androgen.

46. (New) The method of claim 6, wherein the bombesin receptor antagonist is administered to the subject in combination with a neurotransmitter modulator. --

112 112 55K  
Patent Office

REMARKS

Applicants request acknowledgment of the claim of priority made in the Declaration and Preliminary Amendment submitted with the application filing papers.

The Notice of Non-Compliance stated that the amendment filed on July 2, 2002 failed to include a clean version of the amended claims.